Vanderbilt University Medical Center is taking part in a federal clinical trial that seeks to treat effects of Long COVID. 

The trial will repurpose REVERSE-LC, a FDA-approved drug typically used to treat rheumatoid arthritis and lupus. Researchers will monitor motor control, executive function, memory, cardiorespiratory fitness, post-exertional malaise, mental health and quality of life. The Critical Illness, Brain Dysfunction and Survivorship Center and the Vanderbilt Coordinating Center will lead the trial, which is sponsored by National Institutes of Health’s National Institute on Aging.